NCT00337948View on ClinicalTrials.gov

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

February 28, 2005

Conditions
ChemotherapyAnemiaCancer
Interventions
DRUG

Epoetin alfa

All Listed Sponsors
collaborator

Ortho Biotech Products, L.P.

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00337948 - An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks | Biotech Hunter | Biotech Hunter